Top
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial
DOI: 10.1002/onco.13830, Volume: 26, Issue: 8, Pages: e1327-e1338
Article Type: research-article,
Article History
received:
accepted:
published:
-
-
-
- Altmetric
https://www.researchpad.co/tools/openurl?pubtype=&doi=10.1002/onco.13830&title=Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial&author=&keyword=[{keywordId=10444, uniqueName=capecitabine, name=capecitabine, contentId=276320}, {keywordId=10780, uniqueName=lapatinib, name=Lapatinib, contentId=276320}, {keywordId=88001, uniqueName=central-nervous-system-neoplasms, name=central nervous system neoplasms, contentId=276320}, {keywordId=92351, uniqueName=neratinib, name=neratinib, contentId=276320}, {keywordId=338410, uniqueName=receptor-erbb‐2, last=true, name=Receptor, ErbB‐2, contentId=276320}],[{keywordId=10444, uniqueName=capecitabine, name=capecitabine, contentId=276320}, {keywordId=10780, uniqueName=lapatinib, name=Lapatinib, contentId=276320}, {keywordId=88001, uniqueName=central-nervous-system-neoplasms, name=central nervous system neoplasms, contentId=276320}, {keywordId=92351, uniqueName=neratinib, name=neratinib, contentId=276320}, {keywordId=338410, uniqueName=receptor-erbb‐2, last=true, name=Receptor, ErbB‐2, contentId=276320}],[{keywordId=10444, uniqueName=capecitabine, name=capecitabine, contentId=276320}, {keywordId=10780, uniqueName=lapatinib, name=Lapatinib, contentId=276320}, {keywordId=88001, uniqueName=central-nervous-system-neoplasms, name=central nervous system neoplasms, contentId=276320}, {keywordId=92351, uniqueName=neratinib, name=neratinib, contentId=276320}, {keywordId=338410, uniqueName=receptor-erbb‐2, last=true, name=Receptor, ErbB‐2, contentId=276320}],[{keywordId=10444, uniqueName=capecitabine, name=capecitabine, contentId=276320}, {keywordId=10780, uniqueName=lapatinib, name=Lapatinib, contentId=276320}, {keywordId=88001, uniqueName=central-nervous-system-neoplasms, name=central nervous system neoplasms, contentId=276320}, {keywordId=92351, uniqueName=neratinib, name=neratinib, contentId=276320}, {keywordId=338410, uniqueName=receptor-erbb‐2, last=true, name=Receptor, ErbB‐2, contentId=276320}],[{keywordId=10444, uniqueName=capecitabine, name=capecitabine, contentId=276320}, {keywordId=10780, uniqueName=lapatinib, name=Lapatinib, contentId=276320}, {keywordId=88001, uniqueName=central-nervous-system-neoplasms, name=central nervous system neoplasms, contentId=276320}, {keywordId=92351, uniqueName=neratinib, name=neratinib, contentId=276320}, {keywordId=338410, uniqueName=receptor-erbb‐2, last=true, name=Receptor, ErbB‐2, contentId=276320}],&subject=
© 2024 Newgen KnowledgeWorks |
Privacy & Cookie Policy | Powered by: Nova